Navigation Links
Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis
Date:10/30/2013

EXTON, Pa., Oct. 30, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. rheumatologists are moderately satisfied with the currently available biologic agents as well as Pfizer's Xeljanz for the treatment of rheumatoid arthritis (RA). Physicians have a strong preference for the more established, market-leading TNF-alpha inhibitors, Amgen/Pfizer's Enbrel and AbbVie's Humira, over other biologic agents and Xeljanz.  Surveyed physicians rated Enbrel and Humira highest in product satisfaction, perceive these agents as having the most favorable benefit/risk profiles, and they indicate that both products outperform other TNF-alpha inhibitors on the most important stated attributes to prescribing RA therapies. Consequently, these two biologic therapies are used typically as first- or second-line biologic treatment after conventional disease-modifying antirheumatic drug (DMARD) therapy failure.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)

The TreatmentTrends®:Rheumatoid Arthritis (US) report finds that rheumatologists participating in this study also rated Xeljanz, the newest entrant in the RA market, moderately. However, Xeljanz was rated significantly lower than all biologics on overall product performance. In addition, Xeljanz has yet to carve out a distinct place in the RA treatment algorithm. Physicians reported using the product most often after one to three TNF-alpha inhibitor failures. The report also finds that only 14 percent of Xeljanz patients were biologic naive.

"Xeljanz was on the market 9 months at the time this study was fielded, so rheumatologists may not be certain as to which patient types would benefit most from Xeljanz, which is why they are trying it on different patient types at various points in the treatment algorithm," said BioTrends Senior Director Greta Unger. "A relatively low percentage of Xeljanz patients were biologic naive even though it has been approved for use in this patient group. It will be interesting to see if physicians' behavior changes over time as they gain more experience with the product."

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
2. At One Month Post-Launch, Nearly a Quarter of Surveyed U.S. Oncologists Have Prescribed Tafinlar for Malignant Melanoma, Compared to 15 Percent Who Used Mekinist
3. Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates
4. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
5. Surveyed U.S. Neurologists Report Greater Overall Satisfaction with Tecfidera than with Platform Injectables and Other Oral Multiple Sclerosis Therapies
6. At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients
7. A Significant Share of Surveyed Treatment-Naive and Prior Failure HCV Patients Plan to Initiate an HCV Treatment Regimen in the Next Year
8. Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen Idecs Tecfidera to be a Breakthrough in the Treatment of Multiple Sclerosis
9. Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinsons Disease on Their Largest Commercial Plan
10. The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
11. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 Research and Markets ... Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), By ... 2014 - 2025" report to their offering. ... The Latin American pharmaceutical contract ... by 2025 Low drug registration cost in Latin ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most attractive market ... period Mobile X-Ray segment is the largest segment ... market, which is estimated to be valued at more than ... 7% over the forecast period. Mobile X-Ray segment is expected ... Mn in 2017 over 2016. The segment,s revenue in the ...
(Date:4/19/2017)... , April 19, 2017 Global Prostate ... report on the prostate cancer therapeutics market analyzes ... market. Increasing prevalence of prostate cancer, launch of ... the development of new drugs & therapeutic biological ... drug due to lesser side effects are some ...
Breaking Medicine Technology:
(Date:4/21/2017)... IL (PRWEB) , ... April 21, 2017 , ... Chicago ... revolutionize the removal of osteoma. An osteoma is a benign bony lump located on ... the eye and can cause difficulties with sight and pain. Dr. Shah has discovered ...
(Date:4/21/2017)... Lake City, Colo. (PRWEB) , ... April 21, 2017 , ... ... launch of the Flex House, the next project in the company’s esteemed VISION House ... to help homeowners use exactly the amount of resources they need to live affordably ...
(Date:4/21/2017)... ... April 21, 2017 , ... The ... A Week of Addiction and Recovery Education, from April 24 to April 28, ... substance use disorders. , The mission of AWARE is to instill a ...
(Date:4/21/2017)... MD (PRWEB) , ... April ... ... accreditation organization promoting quality-based imaging practices, is seeking candidates to serve on ... for diagnostic imaging. , “RadSite’s ultimate mission is improving image quality ...
(Date:4/21/2017)... ... April 21, 2017 , ... Each year, everyone is urged to ... clean, plant trees and look forward to a better future. However, supporting the environment ... outdoors. Indoor air quality can be two to five times more polluted than outdoor ...
Breaking Medicine News(10 mins):